Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus

Journal of Medicinal Chemistry

Volumn 50, Issue 20, 2007, Pages 4898-4908

  Xie, Hui ^a,e   Ng, Danny ^b,f   Savinov, Sergey N ^b,g   Dey, Barna ^c   Kwong, Peter D ^c   Wyatt, Richard ^c   Smith III, Amos B ^b   Hendrickson, Wayne A ^a,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e Elusys Therapeutics Inc   (United States)

^f FIBROGEN INC   (United States)

^g PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,5' DITHIOBIS(2 NITROBENZOIC ACID); ACETAMIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CYSTEINE; DISULFIDE; GLYCOPROTEIN GP 120; HALOGEN; IODOACETAMIDE; MUTANT PROTEIN; N ETHYLMALEIMIDE; PHENYLALANINE; REAGENT; RECOMBINANT PROTEIN;

ARTICLE; CHEMICAL MODIFICATION; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIGAND BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; VIRUS CELL INTERACTION;

ACETAMIDES; ANTIGENS, CD4; BINDING SITES; BINDING, COMPETITIVE; DISULFIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ENVELOPE PROTEIN GP120; HIV-1; LIGANDS; MODELS, MOLECULAR; MUTATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34948866732     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070564e     Document Type: Article

References (53)

1. Barre-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220 (4599), 868-871.
2. Gallo, R. C.; Salahuddin, S. Z.; Popovic, M.; Shearer, G. M.; Kaplan, M.; Haynes, B. F.; Palker, T. J.; Redfield, R.; Oleske, J.; Safai, B.; White, G.; Foster, P.; Markham, P. D. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984, 224 (4648), 500-503.
3. De Clercq, E. Emerging anti-HIV drugs. Expert Opin. Emerging Drugs 2005, 10 (2), 241-273.
4. Klatzmann, D.; Champagne, E.; Chamaret, S.; Gruest, J.; Guetard, D.; Hercend, T.; Gluckman, J. C.; Montagnier, L. T-Lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312 (5996), 767-768.
5. Dalgleish, A. G.; Beverley, P. C.; Clapham, P. R.; Crawford, D. H.; Greaves, M. F.; Weiss, R. A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312 (5996), 763-767.
6. Trkola, A.; Dragic, T.; Arthos, J.; Binley, J. M.; Olson, W. C.; Allaway, G. P.; Cheng-Mayer, C.; Robinson, J.; Maddon, P. J.; Moore, J. P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384 (6605), 184-187.
7. Wu, L.; Gerard, N. P.; Wyatt, R.; Choe, H.; Parolin, C.; Ruffing, N.; Borsetti, A.; Cardoso, A. A.; Desjardin, E.; Newman, W.; Gerard, C.; Sodroski, J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384 (6605), 179-183.
8. Dimitrov, A. S.; Xiao, X.; Dimitrov, D. S.; Blumenthal, R. Early intermediates in HIV-1 envelope glycoprotein-mediated fusion triggered by CD4 and co-receptor complexes. J. Biol. Chem. 2001, 276 (32), 30335-30341.
9. Furuta, R. A.; Wild, C. T.; Weng, Y.; Weiss, C. D. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 1998, 5 (4), 276-279.
10. Lu, M.; Blacklow, S. C.; Kim, P. S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 1995, 2 (12), 1075-1082.
11. Weissenhorn, W.; Dessen, A.; Harrison, S. C.; Skehel, J. J.; Wiley, D. C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387 (6631), 426-430.
12. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89 (2), 263-273.
13. Kwong, P. D.; Wyatt, R.; Majeed, S.; Robinson, J.; Sweet, R. W.; Sodroski, J.; Hendrickson, W. A. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 2000, 8 (12), 1329-1339.
14. Kwong, P. D.; Wyatt, R.; Robinson, J.; Sweet, R. W.; Sodroski, J.; Hendrickson, W. A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393 (6686), 648-659.
15. Huang, C. C.; Tang, M.; Zhang, M. Y.; Majeed, S.; Montabana, E.; Stanfield, R. L.; Dimitrov, D. S.; Korber, B.; Sodroski, J.; Wilson, I. A.; Wyatt, R.; Kwong, P. D. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310 (5750), 1025-1028.
16. Wyatt, R.; Kwong, P. D.; Desjardins, E.; Sweet, R. W.; Robinson, J.; Hendrickson, W. A.; Sodroski, J. G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998, 393 (6686), 705-711.
17. Sattentau, Q. J.; Moore, J. P.; Vignaux, F.; Traincard, F.; Poignard, P. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J. Virol. 1993, 67 (12), 7383-7393.
18. Thali, M.; Moore, J. P.; Furman, C.; Charles, M.; Ho, D. D.; Robinson, J.; Sodroski, J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 1993, 67 (7), 3978-3988.
19. Thali, M.; Furman, C.; Ho, D. D.; Robinson, J.; Tilley, S.; Pinter, A.; Sodroski, J. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 1992, 66 (9), 5635-5641.
20. Xiang, S. H.; Kwong, P. D.; Gupta, R.; Rizzuto, C. D.; Casper, D. J.; Wyatt, R.; Wang, L.; Hendrickson, W. A.; Doyle, M. L.; Sodroski, J. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 2002, 76 (19), 9888-9899.
21. Chen, B.; Vogan, E. M.; Gong, H.; Skehel, J. J.; Wiley, D. C.; Harrison, S. C Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005, 433 (7028), 834-841.
22. Zhou, T.; Xu, L.; Dey, B.; Hessell, A. J.; Van Ryk, D.; Xiang, S. H.; Yang, X.; Zhang, M. Y.; Zwick, M. B.; Arthos, J.; Burton, D. R.; Dimitrov, D. S.; Sodroski, J.; Wyatt, R.; Nabel, G. J.; Kwong, P. D. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445 (7129), 732-737.
23. Myszka, D. G.; Sweet, R. W.; Hensley, P.; Brigham-Burke, M.; Kwong, P. D.; Hendrickson, W. A.; Wyatt, R.; Sodroski, J.; Doyle, M. L. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (16), 9026-9031.
24. Yuan, W.; Bazick, J.; Sodroski, J. Characterization of the multiple conformational states of free monomelic and trimeric human immunodeficiency virus envelope glycoproteins after fixation by crosslinker. J. Virol. 2006, 80 (14), 6725-6737.
25. Vermeire, K.; Schols, D. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Expert Opin. Invest. Drugs 2005, 14 (10), 1199-1212.
26. Lin, P. F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y. F.; Wang, H. G.; Rose, R.; Yamanaka, G.; Robinson, B.; Li, C. B.; Fridell, R.; Deminie, C.; Demers, G.; Yang, Z.; Zadjura, L.; Meanwell, N.; Colonno, R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (19), 11013-11018.
27. Guo, Q.; Ho, H. T.; Dicker, I.; Fan, L.; Zhou, N.; Friborg, J.; Wang, T.; McAuliffe, B. V.; Wang, H. G.; Rose, R. E.; Fang, H.; Scarnati, H. T.; Langley, D. R.; Meanwell, N. A.; Abraham, R.; Colonno, R. J.; Lin, P. F. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 2003, 77 (19), 10528-10536.
28. Wang, T.; Zhang, Z.; Wallace, O. B.; Deshpande, M.; Fang, H.; Yang, Z.; Zadjura, L. M.; Tweedie, D. L.; Huang, S.; Zhao, F.; Ranadive, S.; Robinson, B. S.; Gong, Y. F.; Ricarrdi, K.; Spicer, T. P.; Deminie, C.; Rose, R.; Wang, H. G.; Blair, W. S.; Shi, P. Y.; Lin, P. F.; Colonno, R. J.; Meanwell, N. A. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3- yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 2003, 46 (20), 4236-4239.
29. Ho, H. T.; Fan, L.; Nowicka-Sans, B.; McAuliffe, B.; Li, C. B.; Yamanaka, G.; Zhou, N.; Fang, H.; Dicker, I.; Dalterio, R.; Gong, Y. F.; Wang, T.; Yin, Z.; Ueda, Y.; Matiskella, J.; Kadow, J.; Clapham, P.; Robinson, J.; Colonno, R.; Lin, P. F. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol. 2006, 80 (8), 4017-4025.
30. Zhao, Q.; Ma, L.; Jiang, S.; Lu, H.; Liu, S.; He, Y.; Strick, N.; Neamati, N.; Debnath, A. K. Identification of N-phenyl-N′- (2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005, 339 (2), 213-225.
31. Si, Z.; Madani, N.; Cox, J. M.; Chruma, J. J.; Klein, J. C.; Schon, A.; Phan, N.; Wang, L.; Biorn, A. C.; Cocklin, S.; Chaiken, I.; Freire, E.; Smith, A. B., III; Sodroski, J. G. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (14), 5036-5041.
32. Madani, N.; Perdigoto, A. L.; Srinivasan, K.; Cox, J. M.; Chruma, J. J.; LaLonde, J.; Head, M.; Smith, A. B., III; Sodroski, J. G. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J. Virol. 2004, 78 (7), 3742-3752.
33. Schon, A.; Madani, N.; Klein, J. C.; Hubicki, A.; Ng, D.; Yang, X.; Smith, A. B., III; Sodroski, J.; Freire, E. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 2006, 45 (36), 10973-10980.
34. Cochran, A. G. Antagonists of protein-protein interactions. Chem. Biol. 2000, 7 (4), R85-R94.
35. Huang, C. C.; Stricher, F.; Martin, L.; Decker, J. M.; Majeed, S.; Barthe, P.; Hendrickson, W. A.; Robinson, J.; Roumestand, C.; Sodroski, J.; Wyatt, R.; Shaw, G. M.; Vita, C.; Kwong, P. D. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure 2005, 13 (5), 755-768.
36. Bohacek, R. S.; McMartin, C. Multiple highly diverse structures complementary to enzyme binding sites: results of extensive application of a de novo design method incorporating combinatorial growth. J. Am. Chem. Soc. 1994, 116 (13), 5560-5571.
37. Ripka, A. S.; Satyshur, K. A.; Bohacek, R. S.; Rich, D. H. Aspartic protease inhibitors designed from computer-generated templates bind as predicted. Org. Lett. 2001, 3 (15), 2309-2312.
38. Arthos, J.; Deen, K. C.; Chaikin, M. A.; Fornwald, J. A.; Sathe, G.; Sattentau, Q. J.; Clapham, P. R.; Weiss, R. A.; McDougal, J. S.; Pietropaolo, C.; Axel, R.; Truneh, A.; Maddon, P. J.; Sweet, R. W. Identification of the residues in human CD4 critical for the binding of HIV. Cell 1989, 57 (3), 469-481.
39. Smith, D. H.; Byrn, R. A.; Marsters, S. A.; Gregory, T.; Groopman, J. E.; Capon, D. J. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 1987, 238 (4834), 1704-1707.
40. Gadek, T. R. Strategies and methods in the identification of antagonists of protein-protein interactions. BioTechniques 2003, Suppl., 21-24.
41. Carr, R.; Jhoti, H. Structure-based screening of low-affinity compounds. Drug Discovery Today 2002, 7 (9), 522-527.
42. Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.; Stroud, R. M.; Gordon, E. M.; Wells, J. A. Site-directed ligand discovery. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (17), 9367-9372.
43. Smith, A. B., III; Savinov, S. N.; Manjappara, U. V.; Chaiken, I. M. Peptide-small molecule hybrids via orthogonal deprotection-chemoselective conjugation to cysteine-anchored scaffolds. A model study. Org. Lett. 2002, 4 (23), 4041-4044.
44. Martin, L.; Stricher, F.; Misse, D.; Sironi, F.; Pugniere, M.; Barthe, P.; Prado-Gotor, R.; Freuion, I.; Magne, X.; Roumestand, C.; Menez, A.; Lusso, P.; Veas, F.; Vita, C. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol. 2003, 21 (1), 71-76.
45. Allaway, G. P.; Davis-Bruno, K. L.; Beaudry, G. A.; Garcia, E. B.; Wong, E. L.; Ryder, A. M.; Hasel, K. W.; Gauduin, M. C.; Koup, R. A.; McDougal, J. S.; Maddon, P. J. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 1995, 11 (5), 533-539.
46. Gauduin, M. C.; Allaway, G. P.; Maddon, P. J.; Barbas, C. F., 3rd; Burton, D. R.; Koup, R. A. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules. J. Virol. 1996, 70 (4), 2586-2592.
47. Trkola, A.; Pomales, A. B.; Yuan, H.; Korber, B.; Maddon, P. J.; Allaway, G. P.; Katinger, H.; Barbas, C. F., 3rd; Burton, D. R.; Ho, D. D.; et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 1995, 69 (11), 6609-6617.
48. Arthos, J.; Cicala, C.; Steenbeke, T. D.; Chun, T. W.; Dela Cruz, C.; Hanback, D. B.; Khazanie, P.; Nam, D.; Schuck, P.; Selig, S. M.; Van Ryk, D.; Chaikin, M. A.; Fauci, A. S. Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J. Biol. Chem. 2002, 277 (13), 11456-11464.
49. Culp, J. S.; Johansen, H.; Hellmig, B.; Beck, J.; Matthews, T. J.; Delers, A.; Rosenberg, M. Regulated expression allows high level production and secretion of HIV-1 gp120 envelope glycoprotein in Drosophila Schneider cells. Biotechnology (N. Y.) 1991, 9 (2), 173-177.
50. Dey, B.; Pancera, M.; Svehla, K.; Shu, Y.; Xiang, S. H.; Vainshtein, J.; Li, Y.; Sodroski, J.; Kwong, P. D.; Mascola, J. R.; Wyatt, R. Characterization of human immunodeficiency virus type 1 monomelic and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J. Virol. 2007, 81 (11), 5579-5593.
51. Korber, B.; Foley, F.; Kuiken, C.; Pillai, S.; Sodroski, J. Numbering Positions in HIV Relative to HXBc2. In Human Retroviruses and AIDS; Korber, B., Kuiken, C. L,; Foley, B., Hahn, B., McCutchan, F., Mellors, J. W., Sodroski, J., Eds.; Los Alamos National Laboratory: Los Alamos, NM, 1998; pp III-102 through IV-103.
52. Osburne, M. S.; Neidhardt, E. A.; Godoy, J. E.; van Schravendijk, M. R.; Grossman, T. H. Production of secreted, soluble human two-domain CD4 protein in Escherichia coli. J. Immunol. Methods 1999, 224 (1-2), 19-24.
53. Coligan, J. E.; Dunn, B. M.; Ploegh, H. L.; Speicher, D. W.; Wingfield, P. T. Current Protocols in Protein Science; John Wiley & Sons: 2001.